Overview

celldx™ is a tissue-based comprehensive molecular profiling test that analyses a broad range of genomic alterations in solid tumours. The test evaluates mutations, gene fusions, copy number changes and other molecular features that may be relevant to targeted treatment strategies.

Assessment of biomarkers linked to immunotherapy response, including tumour mutational burden, PD-L1 expression and microsatellite instability or mismatch repair status, can provide additional context when considering treatment options. This information may help support personalised oncology management in appropriate clinical settings.

Results are interpreted alongside tumour type, disease stage, previous treatment exposure and overall specialist assessment. Integrating genomic findings with clinical evaluation may help guide therapy selection, clinical trial consideration or ongoing treatment planning.